Form 4: Intra-Cellular Therapies Executive Mark Neumann Reports Stock Transactions

EVP, Chief Commercial Officer of Intra-Cellular Therapies, Mark Neumann, reports acquisition of shares through vested performance-based restricted stock units (PRSUs) and shares withheld for tax obligations.

Summary

• On January 31, 2025, Mark Neumann, EVP, Chief Commercial Officer of Intra-Cellular Therapies, Inc., acquired 11,017 shares of common stock through the vesting of performance-based restricted stock units (PRSUs).
• These PRSUs were granted on March 10, 2022, under the company's Amended and Restated 2018 Equity Incentive Plan.
• Also on January 31, 2025, 4,729 shares were withheld by the issuer to cover tax obligations related to the vesting of the PRSUs.
• On February 3, 2025, Neumann was granted 22,727 restricted stock units, which vest in three equal annual installments starting on the first anniversary of the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document primarily reports routine stock transactions related to executive compensation. The vesting of PRSUs suggests positive performance, but the tax withholding is a neutral event.

Positives

• The vesting of PRSUs indicates that performance criteria were met, which could be viewed positively.

Negatives

• The withholding of shares to cover tax obligations reduces the number of shares directly held by the reporting person.

Future Outlook

The reporting person will receive shares from the restricted stock units granted on February 3, 2025, in three equal annual installments beginning on the first anniversary of the grant date.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the equity-based compensation of key personnel.

Comparison to Industry Standards

• Equity compensation is a standard practice in the pharmaceutical industry to align executive interests with shareholder value.
• Companies like Eli Lilly, Pfizer, and AbbVie also utilize restricted stock units and performance-based awards as part of their executive compensation packages.
• The vesting schedules and performance criteria for these awards vary across companies based on their specific goals and industry benchmarks.

Stakeholder Impact

• Shareholders are informed about changes in beneficial ownership by a key executive.
• Employees may be interested in the details of the company's equity incentive plan.

Key Dates

Keywords

Intra-Cellular Therapies, ITCI, Form 4, Beneficial Ownership, Mark Neumann, Restricted Stock Units, PRSUs, Vesting, Tax Withholding, Equity Incentive Plan